Research Dive Market Watch| Gastric Cancer Market: Industry Dynamics

Gastric cancer, also recognized as stomach cancer, originates in the stomach lining, and can be categorized into various types depending on tumor location and cell type. The most prevalent forms are adenocarcinoma and lymphoma. Adenocarcinoma arises from glandular cells within the stomach lining, constituting a significant portion of gastric cancer cases. These glandular cells typically produce mucus and digestive fluids. Conversely, lymphoma emerges from immune system cells present in the stomach. Both types of cancer can present with diverse symptoms, including indigestion, abdominal discomfort, weight loss, and loss of appetite. Early detection is crucial for effective treatment, which may involve surgery, chemotherapy, radiation therapy, or a combination of these approaches. Understanding the distinctions between the types of gastric cancer aids in tailoring treatment strategies for patients, potentially improving outcomes and quality of life.??

According to Research Dive Manager Surya Sanka, the gastric cancer market is estimated to generate a revenue of USD 10,737.0 million by the end of 2031 increasing from USD 2,100.0 million in 2021.??

Increasing Prevalence of Gastric Cancer?

The rising prevalence of gastric cancer is poised to escalate the demand for innovative and more effective treatments. Globally, gastric cancer presents a significant health challenge, with approximately one million new cases being diagnosed annually. In addition, The American Cancer Society’s predicts for stomach cancer in the US for 2024 would be approximately 26,890 new cases. Numerous factors contribute to this escalating incidence, including demographic shifts towards an aging population, prevalent unhealthy lifestyle habits such as smoking and poor dietary choices, and infections caused by Helicobacter pylori, a bacterium notorious for inducing chronic inflammation of the stomach lining. Notably, the advent of targeted therapies and immunotherapies has demonstrated remarkable efficacy in addressing gastric cancer, positioning them as pivotal drivers of market growth in the foreseeable future. The imperative for efficacious treatments highlights an increasing demand, particularly in the realms of targeted therapies and immunotherapies, as the medical community strives to meet the insistent needs of individuals afflicted by this formidable disease.?

High Cost of the Equipment Impacts the Market Growth?

The treatment of gastric cancer presents a significant financial burden, serving as a formidable restraint on the expansion of the gastric cancer market. Its treatment protocol typically encompasses a multifaceted approach, incorporating surgery, chemotherapy, radiation therapy, and targeted therapy. Additionally, post-treatment care demands continuous monitoring and follow-up, compounding the already high costs. This economic strain poses a considerable challenge to accessing care, particularly in low- and middle-income nations where healthcare resources are often scarce. Consequently, individuals in such regions may face obstacles in obtaining timely diagnosis and treatment, exacerbating the potential negative impact on patient outcomes. These financial barriers reflect as a major obstacle expected to hinder the growth trajectory of the gastric cancer market in the foreseeable future.?

Latest Strategic Initiatives Adopted by Market Players?

On February 28, 2024, BeiGene has recently announced that the US Food and Drug Administration (FDA) has acknowledged the submission of a biologics license application (BLA) for TEVIMBRA (tislelizumab), intended for the treatment of advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma. TEVIMBRA, classified as a humanized immunoglobulin G4 (IgG4) anti-programmed cell death protein 1 (PD-1) monoclonal antibody, is administered in conjunction with chemotherapy. The regulatory decision regarding the application is scheduled for December 2024 within the US. The BLA submission is grounded on comprehensive data stemming from the global Phase III RATIONALE-305 clinical trial, encompassing 997 patients diagnosed with advanced unresectable or metastatic G/GEJ adenocarcinoma. Notably, the trial's primary endpoint was the assessment of overall survival (OS). This development marks a significant milestone in potentially expanding treatment options for individuals grappling with advanced stages of G/GEJ adenocarcinoma, thereby highlighting the therapeutic promise and clinical significance of TEVIMBRA in addressing the urgent medical needs of affected patients.?

On February 12, 2024, Merck has received approval from Health Canada for KEYTRUDA (pembrolizumab), their anti-PD-1 therapy, in conjunction with trastuzumab, fluoropyrimidine-, and platinum-based chemotherapy. This approval is specifically for the initial treatment of adult patients with locally advanced unresectable or metastatic HER2 positive gastric or gastroesophageal junction (GEJ) adenocarcinoma, whose tumors express PD-L1 (Combined Positive Score [CPS] ≥ 1) as determined by a validated test. The decision was based on data from the Phase 3 KEYNOTE-811 trial, which exhibited a statistically significant advancement in progression-free survival (PFS) in comparison to placebo when used alongside trastuzumab and chemotherapy in the intention-to-treat (ITT) study population. This highlight signifies a significant step forward in addressing the therapeutic needs of individuals grappling with these aggressive forms of cancer, providing a potentially effective treatment option for this patient population.?

A Bright Future for the Industry?

The landscape of gastric cancer treatment is witnessing a notable transformation with recent strategic initiatives from prominent market players. With its BLA submission to the FDA for advanced gastric or gastroesophageal junction adenocarcinoma treatment, BeiGene plans to hit a milestone in the industry with TEVIMBRA. This submission, supported by comprehensive data from the RATIONALE-305 trial, holds promise for expanding therapeutic options, addressing the urgent medical needs of affected patients. Similarly, Merck's KEYTRUDA approval from Health Canada for the initial treatment of locally advanced or metastatic HER2 positive gastric or gastroesophageal junction adenocarcinoma expressing PD-L1 marks an achievement for the industry. These strategic advancements underscore the growing emphasis on targeted therapies and immunotherapies, reflecting a shift towards personalized and efficacious treatment modalities.??

As the gastric cancer market evolves with innovative approaches, these developments signal a pivotal era in addressing the escalating burden of this disease and improving patient outcomes on a global scale. For further strategic insights, get in touch with Rdive analysts .?